Vinod Das

Co-founder & COO

Biography

Once you realize biological age is measurable and adjustable, it is impossible to think about anything else. The impact and upside from longevity interventions will define our generation – are you ready to join the fight?

Vinod Das

Organizational Development

Biography

Organizational design, effectiveness and transformation executive in the biopharmaceutical industry. I have led the redesign of global and country-based R&D organizations for 3 multinational companies and delivered nearly $ 1 billion in operational value through R&D acceleration.

Vinod Das

CSO

Biography

Advancing drug discovery with innovation and technology.

Winner of CSO’s award for innovation.

Co-led medicinal chemistry

Co-led the research informatics guiding team

Extensive experience in identifying and evaluating various companies and technologies to drive innovation in discovery.

Built, led, and managed high throughput screening, protein crystallography, SPR, compound management, NMR spectroscopy, bioinformatics, cheminformatics, molecular modeling, and high throughput purification.

Build and leads high-functioning teams.

Works across infection, pain, oncology, inflammation, metabolic disease, and Alzheimer’s.

Led external science relationships with Evotec, Biofocus, Forma, Heptares, Beactica, and multiple postdoctoral fellows.

Marcin von Grotthuss

Principal Scientist

Arnold S. Lippa

Chief Scientific Officer, Executive Chairman of Board of Directors

Vinod Das

Associate Director

Biography

Experienced techno-functional leader with demonstrated history of empirical contributions to Consumer Health, Healthcare, Pharmaceuticals, Research Laboratories, Automotive & Aerospace Domains

Highly organized, self-motivated, innovative and science-driven strategist with working experiences as Director, Delivery Manager, Solutions Architect, Lab Informatics (LIMS/ELN), Development & Applications Maintenance for R&D systems.

Well-versed in working with diverse cultures providing effective & tangible outcomes through smart directional leadership. Always embracing & measuring team goals for OKR’s [Objectives and Key Results]

Margaret K Offermann

CEO

Biography

Margaret K. Offermann, MD, PhD is a medical oncologist, tumor biologist, educator and executive with professional experience in academic, philanthropic and private sectors. She is the CEO of OncoSpherix, a preclinical stage cancer drug development company that is advancing a first-in-class family of small molecules that block the ability of cancer cells to adapt and spread from regions of low oxygen that results from growing faster than the blood supply.

Dr. Offermann previously served as Managing Partner of the Salutramed Group (a boutique C-level consulting group), Deputy National Vice President for Research at the American Cancer Society and Professor of Hematology and Oncology at Emory University, where she served as co-director of the MD, PhD training program, Associate Director of the Postgraduate Training Program in Hematology and Oncology and Associate Director of the Winship Cancer Institute.

She has served in executive roles with numerous non-profit organizations, including serving as President of the Federation of American Societies for Experimental Biology (FASEB), a federation of 30 non-profit research societies with over 130,000 members that advances biological science through collaborative advocacy for research policies that promote scientific progress and education.

John Lu

President & CEO

Biography

John Lu is currently the President and CEO of HebeCell Corporation. Established in April of 2016, HebeCell focuses on the fields of Immunotherapy and Regenerative Medicine. Our mission is to develop and commercialize human iPSC-based cell therapeutics for multiple human diseases.

HebeCell has developed a platform technology using a scalable 3-D bioreactor system for the expansion and differentiation of human iPSCs towards immune and other lineages. Based on this 3D platform, HebeCell currently has two ongoing programs: 1) Immunotherapy Program: human iPSC-derived off-the-shelf CAR-NK Cells for the treatment of multiple tumours including blood and solid tumours, as well as autoimmune and infectious diseases; 2) Ocular Program: human iPSC-derived photoreceptor progenitors for the treatment of macular degeneration including Retinitis Pigmentosa, Stargardt’s Disease and Age-related Macular Degeneration (AMD).

Before establishing HebeCell, John was the Senior Director of Research at Advanced Cell Technology/Ocata Therapeutics from 2005 to 2016, which was acquired by Astellas in 2016, the 2nd largest pharmaceutical company in Japan. During his tenure at ACT/Ocata, John developed the hemangioblast, red blood cell, MK/platelet and MSC programs, as well as photoreceptor and retinal ganglion cell programs.

James Leamon

Director, Biologics Device Development

Biography

Medical device and drug-device combination product development leader, engineering director, manufacturing manager and experienced in working across functions and business groups in varying organizations. Have successfully brought new and effective products to market throughout the world, and developed and implemented new engineering, quality control and manufacturing processes. Lead Product Development, and Engineering teams.

Highly experienced and proficient in engineering and project management activities: strategic planning, design engineering, manufacturing engineering, design control, prioritization, contract engineering management, resource allocation, new product and process development.

Specialties: Product development, project leadership and project management, combination product medical devices, laboratory process automation, regulatory standards and process, cross-functional communication, engineering management, product development

Rangaprasad Sarangarajan

Chief Scientific Officer

Neelima Khairatkar-Joshi

Founder and President